KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to -$69.9 million.

  • Arbutus Biopharma's Income from Continuing Operations rose 60.81% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 44.89%. This contributed to the annual value of -$69.9 million for FY2024, which is 4.02% up from last year.
  • As of FY2024, Arbutus Biopharma's Income from Continuing Operations stood at -$69.9 million, which was up 4.02% from -$72.8 million recorded in FY2023.
  • Arbutus Biopharma's 5-year Income from Continuing Operations high stood at -$63.7 million for FY2020, and its period low was -$76.2 million during FY2021.
  • Over the past 3 years, Arbutus Biopharma's median Income from Continuing Operations value was -$69.9 million (recorded in 2024), while the average stood at -$70.7 million.
  • Per our database at Business Quant, Arbutus Biopharma's Income from Continuing Operations spiked by 58.53% in 2020 and then declined by 19.61% in 2021.
  • Over the past 5 years, Arbutus Biopharma's Income from Continuing Operations (Yearly) stood at -$63.7 million in 2020, then dropped by 19.61% to -$76.2 million in 2021, then grew by 8.91% to -$69.5 million in 2022, then declined by 4.89% to -$72.8 million in 2023, then grew by 4.02% to -$69.9 million in 2024.